Efficacy and safety of apremilast, an oral phosphodiesterase 4 inhibitor, in patients with moderate‐to‐severe plaque psoriasis over 52 weeks: a phase III, randomized controlled trial (ESTEEM 2)

Supporters

Support the authors with ResearchCoin

Tip RSC

Journal

British Journal of Dermatology

Topics

Medicine

Immunology

Pathology

Physiology

Dermatology

Show all topics

DOI

10.1111/bjd.14164

License

CC-BY-NC-ND

Other Formats

PDF